➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
McKesson

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NITROLINGUAL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for NITROLINGUAL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00491907 ↗ Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure Terminated University of Zurich Phase 4 2004-10-01 The randomized, double-blind, placebo-controlled study aim to evaluate the effect of 1-month therapy with folic acid (5 mg/day) on endothelial function and baroreceptor function in patients with heart failure. Endothelial function will be studied non-invasively with flow-mediated dilation while for eveluating baroreceptor function sympathetic nervous system activity will be measured directly with microneurography in baseline condition and during infusion of sodium-nitroprusside.
NCT01715220 ↗ Treatment of Suspected Cholelithiasis With Nitroglycerin Recruiting United States Naval Medical Center, San Diego Phase 2 2014-10-01 ABSTRACT: Sublingual nitroglycerin has been advocated for the treatment of acute pain from suspected symptomatic cholelithiasis. There is, however, no clinical studies that validate its use. This study is designed to evaluate the efficacy of nitroglycerine in relieving acute pain of suspected biliary tract origin. Nitroglycerin is a potent smooth muscle relaxant used for biliary tract dilation during ERCP, (Chelly, J) and has been recommended for treatment of biliary colic based on anecdotal experience and small case reports. Nitroglycerin effect is a result of the nitric oxide component of the medication which acts as a smooth muscle relaxant in vascular, bronchial, esophageal and biliary smooth muscles. [McGowan(1936), Chelly (1979),Toyoyama (2001)] The typical dose of nitroglycerin is 0.4 mg given sublingually in pill form or, more recently, in a metered spray form. In a case series reported by Hassel (1993), positive response times ranged from 20 to 60 seconds with duration of action of two to twelve hours. Sublingual nitroglycerin is most commonly used for treatment of chest pain related to insufficient cardiac perfusion. It has also been noted to relieve the pain of esophageal spasms. Nitroglycerin has an excellent safety profile if used in patients with adequate pretreatment blood pressures. [Newberry (2005), Nitroglycerine (2011), Nitro (2011), Wolters (2009)] This study proposes to compare sublingual 0.4 mg doses of nitroglycerin to placebo for the initial treatment of acute pain from suspected symptomatic cholelithiasis
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NITROLINGUAL

Condition Name

Condition Name for NITROLINGUAL
Intervention Trials
Heart Failure 1
COLIC 1
BILIARY TRACT DISEASES 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NITROLINGUAL
Intervention Trials
Heart Failure 1
Gallstones 1
Cholelithiasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NITROLINGUAL

Trials by Country

Trials by Country for NITROLINGUAL
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NITROLINGUAL
Location Trials
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NITROLINGUAL

Clinical Trial Phase

Clinical Trial Phase for NITROLINGUAL
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NITROLINGUAL
Clinical Trial Phase Trials
Terminated 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NITROLINGUAL

Sponsor Name

Sponsor Name for NITROLINGUAL
Sponsor Trials
University of Zurich 1
United States Naval Medical Center, San Diego 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NITROLINGUAL
Sponsor Trials
Other 1
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.